The Cost–Effectiveness of Regorafenib in the Treatment of Patients With Metastatic Colorectal Cancer (Mcrc) Who Have Progressed After Standard Therapies in Turkey

Value in Health - United Kingdom
doi 10.1016/j.jval.2015.09.1176
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy